Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

MedImmune Gaining Antibodies Through Cellective Acquisition

Sep. 15, 2005

By Jennifer Boggs

Genaera Raising $24.5M, Planning Evizon Phase III

Sep. 13, 2005

By Jennifer Boggs

Genaera Raising $24.5M, Planning Evizon Phase III

Sep. 13, 2005

By Jennifer Boggs

Biogen Idec Cutting Staff To Reduce Costs, Tighten Focus

Sep. 12, 2005

By Jennifer Boggs

Biogen Idec Cutting Staff To Reduce Costs, Tighten Focus

Sep. 12, 2005

By Jennifer Boggs

NeuroHealing Tackling Brain Injury With Dopamine Agonist

Sep. 9, 2005

By Jennifer Boggs

Alliance Shifts Astral Subsidiary To MultiCell, Retains One-Third

Sep. 9, 2005

By Jennifer Boggs

NeuroHealing Tackling Brain Injury With Dopamine Agonist

Sep. 9, 2005

By Jennifer Boggs

Alliance Shifts Astral Subsidiary To MultiCell, Retains One-Third

Sep. 9, 2005

By Jennifer Boggs

Series A Brings OncoMed $14M For Cancer Stem Cell Products

Sep. 8, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 7, 2025
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space
BioWorld
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could...
GLP-1 receptor agonists continue their global victory tour
BioWorld
2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their...
AI drives financings, approvals for APAC med-tech in 2024
BioWorld MedTech
AI pulled in major financings and approvals for Asia med-techs in 2024 as Asia Pacific countries played to individual strengths to maximize AI’s applications in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.